TechCare Trauma

Milvue's TechCare Trauma is a Class II Software as a Medical Device (SaMD) that leverages machine learning to assist clinicians in the detection, localization, and characterization of fractures and elbow joint effusions from 2D X-ray radiographs. By providing summary images, annotated outputs, and structured reports, the device has demonstrated high accuracy in both adult and pediatric populations, significantly improving clinician diagnostic accuracy and sensitivity.

Milvue's TechCare Trauma is a radiological computer-assisted detection and diagnosis software, designated as a Class II medical device (21 CFR 892.2090, product code QBS), which has received substantial equivalency determination, enabling its market release. This software as a medical device (SaMD) is designed to assist clinicians across various care settings, including primary, emergency, urgent, and specialty care, in identifying and characterizing fractures and elbow joint effusions in 2D X-ray radiographs for all age groups, from neonates to adults. The device operates by utilizing machine learning algorithms to analyze X-ray images, providing outputs such as summary images, annotated images with bounding boxes indicating definite findings ("YES") or suspicious areas ("DOUBT"), and structured reports. Performance studies have validated TechCare Trauma's high accuracy in detecting fractures and effusions in both adult and pediatric populations. Importantly, its use significantly improved the diagnostic accuracy and sensitivity of clinicians, thereby enhancing their ability to detect and localize these conditions.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific machine learning algorithms or models does TechCare Trauma employ, and how were they trained and validated to ensure robustness across diverse patient populations?; How does the device's categorization of findings as "YES" (definite) versus "DOUBT" (suspicious) influence clinical decision-making and what is the associated false positive/negative rate for each category?; What was the methodology for the performance studies, including the composition of the validation datasets, types of fractures/effusions included, and the demographics of the pediatric population?; How does the diagnostic accuracy and sensitivity of clinicians using TechCare Trauma compare to a control group of clinicians operating without the software in a blinded, prospective study design?; What are the integration requirements and potential workflow impacts of implementing TechCare Trauma into various clinical settings, such as emergency departments or primary care offices?